Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Cortical Thinning and Neuropsychologic Measures Predict CD19 CAR T Cell Therapy-Associated Neurotoxicity

Agne Taraseviciute, MD, Deepa Bhojwani, MD, Ravi Bansal, PhD, Bradley S Peterson, MD, Michael A Pulsipher, MD, Alan S. Wayne, MD, Courtney Allem, Michael Sheard, PhD, Joey Trampush, PhD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-142609

Published: 2020

Journal Articles

ZUMA-4: A Phase 1/2 Multicenter Study of KTE-X19 in Pediatric and Adolescent Patients With Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Alan S. Wayne, MD, Gerard Michel, MD, Daniel W. Lee, MD, André Baruchel, MD, Sonali Chaudhury, MD, Patrick A. Brown, MD, Michelle Hermiston, MD PhD, Joerg Krueger, MD, Tong Shen, PhD, Kristy Tailford, PhD, Behzad Kharabi Masouleh, MD

Blood (2020) 136 (Supplement 1): 42.

https://doi.org/10.1182/blood-2020-137233

Published: 2020

Journal Articles

Targeting of Integrin α4/VCAM-1 with AVA4746 Modulates the Redox-Status and Metabolism in ALL and Angiogenesis

Ruan Yongsheng, MD, Enzi Jiang, MD PhD, Hye Na Kim, Heather Ogana, Mo Yang, MD, Deepa Bhojwani, MD, Alan S. Wayne, MD, Yong-Mi Kim, MD MPH, PhD

Blood (2019) 134 (Supplement_1): 3881.

https://doi.org/10.1182/blood-2019-132101

Published: 2019

Journal Articles

Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses

Colleen Annesley, MD, Corinne Summers, MD, Michael A. Pulsipher, MD, Alan S. Wayne, MD, Julie Rivers, MD, Adam J. Lamble, MD, Ashley Wilson, PhD, Qian Vicky Wu, PhD, Adam Brand, Stephanie Mgebroff, Christopher Brown, Catherine Lindgren, Julie R. Park, MD, Michael C. Jensen, MD, Rebecca Gardner, MD

Blood (2019) 134 (Supplement_1): 3869.

https://doi.org/10.1182/blood-2019-131447

Published: 2019

Journal Articles

Cell Adhesion of ALL to Stromal Cells May Mediate CAR T-Cell Resistance: A Novel Escape Mechanism for Immunotherapy

Hye Na Kim, Enzi Jiang, MD PhD, Ruan Yongsheng, MD, Heather Ogana, Nour Abdel-Azim, Justin Le, BS, Annie Luong, Halvard Bonig, MD, Nabil Ahmed, MD, Moghimi Babak, MD, Michael A. Pulsipher, MD, Deepa Bhojwani, MD, Alan S. Wayne, MD, Chintan Parekh, MBBS, Hisham Abdel-Azim, Nora Heisterkamp, Yong-Mi Kim, MD MPH, PhD

Blood (2019) 134 (Supplement_1): 2623.

https://doi.org/10.1182/blood-2019-132131

Published: 2019

Journal Articles

Immunologic and Brain Bases of Neurotoxicity Associated with CAR T-Cell Therapy

Deepa Bhojwani, MD, Bradley Peterson, MD, Agne Taraseviciute, MD PhD, Michael A. Pulsipher, MD, Alan S. Wayne, MD, Michael Sheard, PhD, Courtney Allem, Joey Trampush, PhD, Ravi Bansal, PhD

Blood (2019) 134 (Supplement_1): 1946.

https://doi.org/10.1182/blood-2019-127533

Published: 2019

Journal Articles

Minimal Change in CAR T Cell Manufacturing Can Impact in Expansion and Side Effect of the CAR T Cell Therapy

Francesco Ceppi, MD, Colleen Annesley, MD, Olivia Finney, PhD, Corinne Summers, MD, Stephanie Rhea, BS, Isaac C. Jenkins, MS, Qian V. Wu, PhD, Wen Yang, Michael A. Pulsipher, MD, Alan S. Wayne, MD, Julie R. Park, MD, Rebecca Gardner, MD, Michael C. Jensen, MD

Blood (2018) 132 (Supplement 1): 4012.

https://doi.org/10.1182/blood-2018-99-110164

Published: 2018

Journal Articles

Early Response Data for Pediatric Patients with Non-Hodgkin Lymphoma Treated with CD19 Chimeric Antigen Receptor (CAR) T-Cells

Julie Rivers, MD, Colleen Annesley, MD, Corinne Summers, MD, Olivia Finney, PhD, Michael A. Pulsipher, MD, Alan S. Wayne, MD, Julie R. Park, MD, Michael C. Jensen, MD, Rebecca Gardner, MD

Blood (2018) 132 (Supplement 1): 2957.

https://doi.org/10.1182/blood-2018-99-113744

Published: 2018

Journal Articles

High Rates of Minimal Residual Disease-Negative (MRD−) Complete Responses (CR) in Adult and Pediatric and Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) Treated With KTE-C19 (Anti-CD19 Chimeric Antigen Receptor [CAR] T Cells): Preliminary Results of the ZUMA-3 and ZUMA-4 Trials

Blood (2016) 128 (22): 2803.

https://doi.org/10.1182/blood.V128.22.2803.2803

Published: 2016

Journal Articles

AVA4746, an Orally Available, Clinical Grade Antagonist of Integrin Alpha 4, Sensitizes Pre-B Cell Acute Lymphoblastic Leukemia to Chemotherapy

Yongsheng Ruan, MD, Eun Ji Gang, Hye-Na Kim, Chintan Parekh, MBBS, Hisham Abdel-Azim, MD, Deepa Bhojwani, MD, Alan S. Wayne, MD, Yong-Mi Kim, MD PhD MPH

Blood (2016) 128 (22): 2765.

https://doi.org/10.1182/blood.V128.22.2765.2765

Published: 2016

Journal Articles

5-Azacytidine Prevents Relapse from Discrete Bone Marrow Sites in Leukemia Xenografts Treated with CD22-Targeting Immunotoxin Moxetumomab Pasudotox

Fabian Mueller, MD, Tyler Cunningham, Stephanie Stookey, Chin-Hsien Tai, Alan S. Wayne, MD, Ira Pastan, MD

Blood (2016) 128 (22): 2810.

https://doi.org/10.1182/blood.V128.22.2810.2810

Published: 2016

Journal Articles

Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL: A Report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium

Michael J. Burke, MD, Patrick Brown, MD, Richard Sposto, PhD, Lia Gore, MD, Alan S. Wayne, MD

Blood (2016) 128 (22): 2781.

https://doi.org/10.1182/blood.V128.22.2781.2781

Published: 2016

Journal Articles

Immunotoxin Activity Against B-Lineage Leukemia and Lymphoma Is Exposure Time Dependent: Implications for Trial Design

Fabian Mueller, MD PhD, Xiu-Fen Liu, PhD, Alan S. Wayne, MD, Ira Pastan, MD

Blood (2015) 126 (23): 1332.

https://doi.org/10.1182/blood.V126.23.1332.1332

Published: 2015

Journal Articles

The PI3Kdelta Inhibitor, CAL-101, Inhibits Migration of Primary Pre-B ALL to SDF1alpha: Treatment Implications for Overcoming Cell-Adhesion-Mediated Drug Resistance

EunJi Gang, MDPhD, Hye Na Kim, Yann Duchartre, PhD, Stephanie Nicole Shishido, PhD, Sajad Khazal, MD, Etai Adam, MD, Nour Abdel-Azim, Chintan Parekh, MBBS, Hisham Abdel-Azim, MD, Deepa Bhojwani, MD, Nora Heisterkamp, PhD, Alan S. Wayne, MD, Yong-Mi Kim, MDPhDMPH

Blood (2015) 126 (23): 2526.

https://doi.org/10.1182/blood.V126.23.2526.2526

Published: 2015

Journal Articles

Re-Induction Outcome for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: A Retrospective Cohort Study of the Therapeutic Advances in Childhood Leukemia Consortium

Weili Sun, MDPhD, Jemily Malvar, MS, Richard Sposto, PhD, Anupam Verma, MD, Jennifer J. Wilkes, MD, Robyn M. Dennis, MD, Kenneth Matthew Heym, MD, Elena Eckroth, CCRC, Jeannette Vandergiesse, BA, CCRP, Paul S. Gaynon, MD, Alan S. Wayne, MD, James A. Whitlock, MD

Blood (2015) 126 (23): 3760.

https://doi.org/10.1182/blood.V126.23.3760.3760

Published: 2015

Journal Articles

A Novel CD49d Targeting Antisense, ATL1102, Effectively Mobilizes Acute Myeloid Leukemia Cells

Yann Duchartre, PhD, EunJi Gang, MDPhD, Hye Na Kim, Stephanie Nicole Shishido, PhD, Muller Fabbri, MD, Anatoly Grishin, PhD, Chintan Parekh, MBBS, Hisham Abdel-Azim, MD, Deepa Bhojwani, MD, Alan S. Wayne, MD, George Tachas, PhD, Yong-Mi Kim, MDPhDMPH

Blood (2015) 126 (23): 3807.

https://doi.org/10.1182/blood.V126.23.3807.3807

Published: 2015

Journal Articles

The UK ALLR3 Chemotherapy Regimen for Relapsed/Refractory Acute Lymphoblastic Leukemia of Childhood: A Multi-Institutional Retrospective Study of Treatment Related Adverse Events

Weili Sun, MDPhD, Alison Marie Smith, BS, Orgal Etan, MD, Richard Sposto, PhD, Jennifer J. Wilkes, MD, Rebecca A Gardner, MD, Hur Minjun, Vanessa Pineros, Emily Olson, MD, Yijuin Tan, Susan R. Rheingold, MD, Michael J. Burke, MD, Alan S. Wayne, MD

Blood (2014) 124 (21): 3647.

https://doi.org/10.1182/blood.V124.21.3647.3647

Published: 2014

Journal Articles

PI3Kdelta Inhibitor, CAL-101, De-Adheres Primary Pre-B ALL from VCAM-1 and Induces Apoptosis in Primary Pre-B ALL

Sajad Khazal, MD, Enzi Jiang, MD PhD, Stephanie Shishido, Osanna Kosoyan, Kim Hye-Na, Alexa Velasquez, Yao-Te Hsieh, Hisham Abdel-Azim, MD, Ann M Mohrbacher, MD, Akil Merchant, MD, Alan S. Wayne, MD, Nora Heisterkamp, PhD, Yong-Mi Kim, MD MPH, PhD

Blood (2014) 124 (21): 3715.

https://doi.org/10.1182/blood.V124.21.3715.3715

Published: 2014

Journal Articles

Intent-to-Treat Results of a Phase I Trial of CD19 Chimeric Antigen Receptor Engineered T Cells Using a Consistent Treatment Regimen Reveals a 67% Complete Response Rate in Relapsed, Refractory Acute Lymphoblastic Leukemia

Daniel W. Lee, MD, Maryalice Stetler-Stevenson, MD PhD, Marianna Sabatino, MD, Constance Yuan, MD PhD, Terry J Fry, MD, Nirali N Shah, MD, Cindy Delbrook, RN, Bonnie Yates, RN, Hua Zhang, PhD, Ling Zhang, Nick Tschernia, BS, Yongzhi Cui, MD PhD, Steven Feldman, PhD, James N Kochenderfer, MD, Steven A. Rosenberg, MD, PhD, David F. Stroncek, MD, Alan S. Wayne, MD, Crystal L Mackall, MD

Blood (2014) 124 (21): 381.

https://doi.org/10.1182/blood.V124.21.381.381

Published: 2014

Journal Articles

A Phase 1 Study of Azacitidine (AZA) in Combination with Fludarabine and Cytarabine in Relapse/Refractory Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

Weili Sun, MDPhD, Paul S Gaynon, MD, Richard Sposto, PhD, Henrique Bittencourt, MD, Andrew E. Place, MDPhD, Yoav H Messinger, MD, Chris Fraser, MD, Luciano Dalla-Pozza, MD, Jeannette van der Giessen, BA, CCRP, Elena Eckroth, CCRC, Xiaojing Yang, PhD, Gangning Liang, PhD, Peter A. Jones, PhD DSc, Alan S. Wayne, MD, Todd Cooper, DO

Blood (2014) 124 (21): 3764.

https://doi.org/10.1182/blood.V124.21.3764.3764

Published: 2014

NARROW

Cortical Thinning and Neuropsychologic Measures Predict CD19 CAR T Cell Therapy-Associated Neurotoxicity

ZUMA-4: A Phase 1/2 Multicenter Study of KTE-X19 in Pediatric and Adolescent Patients With Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Targeting of Integrin α4/VCAM-1 with AVA4746 Modulates the Redox-Status and Metabolism in ALL and Angiogenesis

Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses

Cell Adhesion of ALL to Stromal Cells May Mediate CAR T-Cell Resistance: A Novel Escape Mechanism for Immunotherapy

Immunologic and Brain Bases of Neurotoxicity Associated with CAR T-Cell Therapy

Minimal Change in CAR T Cell Manufacturing Can Impact in Expansion and Side Effect of the CAR T Cell Therapy

Early Response Data for Pediatric Patients with Non-Hodgkin Lymphoma Treated with CD19 Chimeric Antigen Receptor (CAR) T-Cells

AVA4746, an Orally Available, Clinical Grade Antagonist of Integrin Alpha 4, Sensitizes Pre-B Cell Acute Lymphoblastic Leukemia to Chemotherapy

5-Azacytidine Prevents Relapse from Discrete Bone Marrow Sites in Leukemia Xenografts Treated with CD22-Targeting Immunotoxin Moxetumomab Pasudotox

Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL: A Report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium

Immunotoxin Activity Against B-Lineage Leukemia and Lymphoma Is Exposure Time Dependent: Implications for Trial Design

The PI3Kdelta Inhibitor, CAL-101, Inhibits Migration of Primary Pre-B ALL to SDF1alpha: Treatment Implications for Overcoming Cell-Adhesion-Mediated Drug Resistance

Re-Induction Outcome for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: A Retrospective Cohort Study of the Therapeutic Advances in Childhood Leukemia Consortium

A Novel CD49d Targeting Antisense, ATL1102, Effectively Mobilizes Acute Myeloid Leukemia Cells

The UK ALLR3 Chemotherapy Regimen for Relapsed/Refractory Acute Lymphoblastic Leukemia of Childhood: A Multi-Institutional Retrospective Study of Treatment Related Adverse Events

PI3Kdelta Inhibitor, CAL-101, De-Adheres Primary Pre-B ALL from VCAM-1 and Induces Apoptosis in Primary Pre-B ALL

Intent-to-Treat Results of a Phase I Trial of CD19 Chimeric Antigen Receptor Engineered T Cells Using a Consistent Treatment Regimen Reveals a 67% Complete Response Rate in Relapsed, Refractory Acute Lymphoblastic Leukemia

A Phase 1 Study of Azacitidine (AZA) in Combination with Fludarabine and Cytarabine in Relapse/Refractory Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only